Table 1.
Study characteristics
| Biobank | Ancestry | Sample size | Age, mean (SD) | Women, % | CAD |
T2D |
Breast cancer |
Prostate cancer |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases N = 88,830 | AAO, mean (SD) | Cases N = 110,685 | AAO, mean (SD) | Cases, N = 32,922 | AAO, mean (SD) | Cases, N = 26,700 | AAO, mean (SD) | ||||||
| European ancestry (n = 807,793) | |||||||||||||
| Estonian Biobank | Estonia | EUR | 110,597 | 43.4 (16.0) | 67.3 | 5,064 | 67.5 (11.9) | 7,066 | 60.9 (12.7) | 1,379 | 59.5 (13.4) | 1,202 | 68.7 (9.2) |
| FinnGen | Finland | EUR | 258,402 | 60.3 (17.1)∗ | 56.5 | 25,706 | 64.9 (11.8) | 37,001 | 60.1 (11.9) | 11,573 | 59.0 (11.6) | 8,709 | 68.5 (8.1) |
| HUNT | Norway | EUR | 69,422 | 50.8 (17.0) | 53.0 | 6,594 | 69.0 (12.5) | 5,228 | 68.1 (13.4) | 1,731 | 61.7 (13.4) | 2,224 | 70.6 (9.2) |
| MGB Biobank | United States | EUR | 25,696 | 60.0 (16.5) | 53.1 | 3,206 | – | 5,182 | – | 1,513 | – | 1,593 | – |
| UK Biobank | United Kingdom | EUR | 343,676 | 56.9 (8.0) | 53.7 | 17,986 | 62.1 (8.9) | 13,616 | 54.6 (8.5) | 11,075 | 54.0 (8.1) | 7,429 | 59.7 (6.2) |
| Other ancestry (n = 195,507) | |||||||||||||
| BioBank Japan | Japan | EAS | 178,726 | 63.1 (14.0) | 46.3 | 29,080 | 61.7 | 40,121 | 56.2 | 5,316 | 56.1 | 5,192 | 71.1 |
| MGB Biobank | United States | AFR | 1,535 | 54.1 (16.3) | 61.4 | 285 | – | 660 | – | 64 | – | 80 | – |
| UK Biobank | United Kingdom | AFR | 7,618 | 51.9 (8.1) | 57.0 | 169 | 56.9 (10.3) | 691 | 50.2 (8.9) | 132 | 50.2 (9.1) | 199 | 57.4 (7.4) |
| UK Biobank | United Kingdom | SAS | 7,628 | 53.4 (8.5) | 46.1 | 740 | 58.6 (9.7) | 1,120 | 50.0 (8.7) | 139 | 51.2 (7.9) | 72 | 59.6 (7.2) |
EUR = European, EAS = East Asian, AFR = African (self-reported African/Caribbean in UK Biobank), SAS = South Asian, CAD = coronary artery disease, T2D = type 2 diabetes, AAO = age at onset, SD = standard deviation. Disease definitions are listed by cohort in STAR Methods. In HUNT, we show the age at baseline for those participating in either HUNT2 or HUNT3, and a mean of these baseline ages for individuals participating in both. ∗Age at the end of follow-up.